PENGARUH PEMBERIAN FUROSEMIDE DAN HOMECARE TERHADAP NILAI HbA1c PADA PASIEN GAGAL JANTUNG NON-DIABETIC
(Studi Kasus Di Unit Rawat Jalan Rumah Sakit Angkatan Laut Dr. Ramelan Surabaya)
Abstract
Prevalensi penderita gagal jantung di Indonesia semakin banyak. Salah satu terapi yang sering diberikan adalah Furosemide, dimana secara teori Furosemide dapat mempengaruhi dan meningkatkan nilai HbA1c. Oleh karena itu dilakukan penelitian tentang pengaruh pemberian Furosemide terhadap nilai HbA1c. Penelitian ini menggunakan metode single blind, Randomized Controlled Trial (RCT) untuk menguji pengaruh pemberian Furosemide dan homecare terhadap nilai HbA1c pada pasien gagal jantung non-diabetic yang terbagi secara numerisasi ke dalam kelompok uji dan kelompok kontrol. Kelompok uji mendapatkan Furosemide dan intervensi homecare, sedangkan kelompok kontrol hanya mendapat Furosemide saja. Semua kelompok menjalani pemeriksaan nilai HbA1c pre-test dan post-test untuk melihat perbedaan nilai HbA1c sebelum dan sesudah pemberian Furosemide, serta melihat perbedaan nilai HbA1c sesudah pemberian Furosemide antara kelompok uji dan kelompok kontrol. Penelitian ini menunjukkan adanya perbedaan yang signifikan antara nilai HbA1c sebelum dan sesudah pemberian Furosemide, baik pada kelompok uji (P value = 0,000) dan kelompok kontrol (P value = 0,000); dan tidak adanya perbedaan yang signifikan pada nilai HbA1c sesudah pemberian Furosemide antara kelompok uji dan kelompok kontrol (P value = 0,330). Pemberian Furosemide memberikan pengaruh pada peningkatan nilai HbA1c, sedangkan intervensi homecare tidak berpengaruh pada perubahan nilai HbA1c.
Downloads
References
Riset Kesehatan Dasar (RISKESDAS) Kementerian Kesehatan. 2007.
Lindenfield, JoAnn; et al. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. HFSA 2010 Guideline Executive Summary, Journal of Cardiac Failure Vol. 16 No. 6. 2010. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure. 2010
Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. Nonpharmacologic Management and Health Care Maintenance of Patients with Chronic Heart Failure: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010
Blackburn, David F; and Wilson, Thomas W. Antihypertensive Medications and Blood Sugar: Theories and Implications. Can J Cardiol 2006; 22(3): 229-233
Carter, Barry L; and Ernst, Michael E. Thiazide-Induced Hyperglycemia: Can It Be Prevented? American Journal of Hypertension, volume 22 number 5. 2009. http://ajh.oxfordjournals.org/
Ahmed, A; et al. Heart Failure, Chronic Diuretic Use and Increase in mortality and Hospitalization: An Observational Study Using Propensity Score Methods. Eur Heart J 2006; 27: 1431 – 1439
Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, Bakris GL, Brancati FL, Cushman WC, Oparil S, Wright JT Jr. Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute. Hypertension 2008; 52:30–36.
Elliott WJ, Meyer PM. Incident Diabetes in Clinical Trials of Antihypertensive: a Network Meta-Analysis. Lancet 2007; 369:201-207
FDA Reports: Furosemide and Blood Glucose Increased. 2013. Available http://www.ehealthme.com/ds/furosemide/blood+glucose+increased
Taylor, et al. Antihypertensive Therapy and The Risk of New-Onset Diabetes. Diabetes Care, Volume 29, Number 5, May 2006.
Wright JM, Musini VM. First-Line Drugs for Hypertension. Cochrane Database Syst Rev 2009;CD001841.
Grimm, Christine; Koberlein, Juliane; Wiosna, Waldemar; et al. New-Onset Diabetes and Antihypertensive Treatments. GMS Health Technology Assessment 2010, Vol. 6, ISSN 1861-8863
ohn, Garry. W; Hillson, Rowan; and Alberti, Sir George. Use of Haemoglobin A1C (HbA1C) in The Diagnosis of Diabetes Mellitus: The Implementation of World Health Organization (WHO) Guidance 2011. http://www.who.int/diabetes/publications/report-hba1c_2011.pdf
Phillips, Patrick. J. HbA1c and Monitoring Glycaemia. Australian Family Physician Volume 41, No 1. 2012
- Articles published in CALYPTRA are licensed under a Creative Commons Attribution-ShareAlike 4.0 International license. You are free to copy, transform, or redistribute articles for any lawful purpose in any medium, provided you give appropriate credit to the original author(s) and the journal, link to the license, indicate if changes were made, and redistribute any derivative work under the same license.
- Copyright on articles is retained by the respective author(s), without restrictions. A non-exclusive license is granted to CALYPTRA to publish the article and identify itself as its original publisher, along with the commercial right to include the article in a hardcopy issue for sale to libraries and individuals.
- By publishing in CALYPTRA, authors grant any third party the right to use their article to the extent provided by the Creative Commons Attribution-ShareAlike 4.0 International license.